Utah Med Prods Stock Price, News & Analysis

Utah Medical Products, Inc. (NASDAQ:UTMD) announced a special cash dividend of $2.00 per share, payable on December 29, 2021, to stockholders of record by December 15, 2021. This action replaces the normal quarterly dividend and aims to maximize returns for shareholders. The company reported a cash balance of $64.3 million as of September 30, 2021, despite distributing $3.1 million in dividends earlier this year. Chairman Kevin Cornwell highlighted that this dividend reflects ongoing excellent operating performance and strategic cash management.

Utah Medical Products (Nasdaq: UTMD) reported robust 3Q 2021 financial results, showing a recovery from pandemic-induced dips. Revenues increased by 20% compared to 3Q 2020, with net income rising by 43% to $4,206. Furthermore, 9M 2021 results surpassed 2020, with a 44% rise in net income and earnings per share increased to $2.915. Cost management and a weaker USD further contributed to profitability, with gross profit margins at 64.2%. Notably, cash reserves grew to $64.3 million, reflecting strong operational performance in the medical device sector.

Utah Medical Products (NASDAQ:UTMD) has declared a quarterly cash dividend of $.285 per share, an approximate 2% increase from the prior year. The dividend is payable on October 5, 2021 to shareholders on record by September 16, 2021. The company focuses on developing and manufacturing specialty medical devices aimed at improving health care for women and infants. Their products are recognized in over 100 countries for optimal patient outcomes. For further details, visit www.utahmed.com.

Utah Medical Products reported substantial financial recovery in 2Q 2021, with revenues rising by 43% and net income increasing by 161% compared to 2Q 2020. The company's performance improvement is also evident when compared to 2019, with a 6% rise in revenue for the quarter. Factors such as a weaker U.S. dollar contributed significantly to foreign sales. However, the increase in deferred tax liabilities due to UK tax rate changes was noted. Based on current trends, management anticipates achieving an adjusted EBITDA of $25 million for the full year 2021.

Utah Medical Products, Inc. (Nasdaq: UTMD) announced a quarterly cash dividend of $.285 per share, payable on July 6, 2021, to shareholders of record as of June 15, 2021. This marks a 2% increase from the same quarter last year. The company specializes in developing, manufacturing, and marketing medical devices for women's healthcare and neonatal care, serving clinicians in over 100 countries worldwide.

On April 22, 2021, Utah Medical Products reported its financial results for Q1 2021, highlighting a solid performance despite ongoing pandemic challenges. Key metrics showed a 1% increase in revenues and a 2% rise in gross profit compared to Q1 2020. Operating income also grew by 1%, while net income fell by 4% due to lower non-operating income. Despite challenges in device sales, particularly the Filshie device, the company anticipates a 25% revenue increase for Q2 2021 vs. Q2 2020. Cash and investments reached $56 million, reflecting a healthy balance sheet with no debt.

Utah Medical Products, Inc. (Nasdaq: UTMD) announced the termination of its Shareholder Rights Agreement by unanimous consent of the Board of Directors. Originally approved in 1994 and extended multiple times, the decision reflects evolving corporate governance standards and shareholder feedback. The company focuses on developing specialty medical devices for women and infants, recognized worldwide for their quality. This strategic move aims to align with changing investor expectations and modern governance practices.

Utah Medical Products (NASDAQ:UTMD) has declared a quarterly cash dividend of $.285 per share, to be paid on April 2, 2021, to shareholders on record by March 17, 2021. This dividend reflects a 2% increase compared to the previous year’s quarter. The company remains focused on providing medical devices in the women's health sector, recognized for their quality by clinicians in over 100 countries.

Utah Medical Products (Nasdaq: UTMD) reported its 4Q 2020 financial results showing recovery from pandemic impacts, achieving its best revenue quarter of the year. 4Q 2020 revenues were nearly 2% higher than pre-pandemic 4Q 2019. However, total 2020 revenues were 10% lower than 2019. Direct sales to end users were down 14% for the year, indicative of ongoing challenges. Foreign exchange rates positively impacted 4Q revenues by 1.1%. Operating income margins dropped to 35.6% in 4Q 2020 from 39.5% in 4Q 2019, largely due to increased expenses related to investment and pandemic responses.